UBS analyst Ashwani Verma downgraded Coherus Biosciences (NASDAQ: CHRS) from Buy to Neutral with a price target of $1.50 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE